Deep Blue Medical Advances, Inc. - Innovator in Soft Tissue Surgical Devices

📢 Key Milestones (2024–2026):
   In May 2024, Deep Blue received the Luis Villalobos Award from the Angel Capital Association as the most innovative life Science company of 2024. In April 2026, the company closed an oversubscribed $5.6 million Series A financing round and elevated Lou Fuqua to Chief Operating Officer. In June 2025, the T-Line Hernia Mesh technology was featured by the Association of University Technology Managers (AUTM) Better World Project for its clinical and commercial impact.

Company Profile (Updated April 2026)

Deep Blue Medical Advances, Inc. is a privately held medical device company headquartered in Durham, North Carolina, USA. Founded in 2015 by Dr. Howard Levinson, a plastic surgeon and researcher at DUKe University, the company is dedicated to transforming soft tissue surgery by developing and launching next-generation surgical devices for optimal tissue tension, reinforcement, and defect closure.

The company's flagship product, the T-Line® Hernia Mesh, is the first hernia mesh with integral suture-like extensions designed to eliminate the key point of failure in conventional mesh fixation — the mesh, suture, tissue interface. By distributing force across a wider surface area, T-Line provides 275% greater fixation strength and 15x more surface area than traditional sutures, reducing the risk of suture pull-through (cheesewiring), mesh migration, and hernia recurrence.

Development History:

- 2015: Founded in Durham, NC, by Dr. Howard Levinson, a plastic surgeon at Duke University

- 2020.08: Received FDA 510(k) clearance (K193144) for the T-Line® Hernia Mesh for onlay technique in open ventral hernia repair

- 2020: Initiated U.S. clinical launch of T-Line Hernia Mesh in selected sites

- 2022.06: Closed Series A1 funding round led by BayMed Venture Partners; Gary Gershony joined the Board of Directors

- 2022.12: Received additional FDA 510(k) clearance for the sublay technique in open ventral hernia repair, significantly expanding the addressAble patient population

- 2023: T-Line Hernia Mesh in use at approximately 45 clinical sites across the United States; over 8,000 extensions and lockstitches implanted with no adverse events

- 2024.05: Received the Luis Villalobos Award from the Angel Capital Association as the most innovative life science company of 2024

- 2025.06: T-Line Hernia Mesh technology featured by the Association of University Technology Managers (AUTM) Better World Project, highlighting the innovation's clinical and commercial success

- 2026.04: Closed oversubscribed $5.6 million Series A financing; elevated Lou Fuqua to Chief Operating Officer

Core Mission: To transform soft tissue surgery by developing next-generation surgical devices that prevent failure due to suture pull-through, reduce patient pain, and provide superior surgical experiences and outcomes.

Core Product Portfolio

T-Line® Hernia Mesh (Commercial)

- Design: Thin, medium-weight, large-pore polymeric mesh with integral suture-like extensions and integrated fixation needles

- Indication: Reinforcement of soft tissue where weakness exists for the repair of ventral hernias via open onlay or sublay approACH in adults

- Key Features: 15x more surface area for fixation than traditional sutures; 275% greater fixation strength; ravel-resistant patent-pending weave; excellent bio-incorporation

- Clinical Use: Approximately 45 U.S. clinical sites; over 8,000 extensions implanted with no adverse events; 15 published manuscripts and 27 conference presentations

- FDA Status: 510(k) cleared (K193144) for onlay and sublay techniques

T-Line® TCS — Tissue Control Suture (In Development)

- Description: Novel suture technology designed to make soft tissue procedures quicker, safer, and more durable

- Benefit: Potential for less pain due to reduced cheesewiring effect

- Status: Under development; Investigational Use Only

T-Line® Scaffold for Breast Surgery (In Development)

- Description: Application of T-Line technology to breast reconstruction and soft tissue support

- Status: Under development; Investigational Use Only

Anchor Clip (In Development)

- Description: Absorbable anchoring device for potentially faster, easier implantation of mesh and soft tissue reinforcement

- Status: Under development; Investigational Use Only

Future Pipeline

- Biosynthetic Version: Bioresorbable variant of the T-Line Hernia Mesh

- Coated Composite Version: Anti-adhesion coated T-Line Mesh for minimally invasive (laparoscopic) surgery

Clinical Evidence & Market Impact

- Published Data: 15 peer-reviewed manuscripts and 27 conference presentations supporting T-Line Hernia Mesh safety and efficacy

- Anchor Strength: Benchtop testing demonstrates ~275% greater anchoring strength than standard of care in the perioperative period

- Market Need: Approximately 600,000 abdominal hernia repairs performed annually in the U.S.; long-term failure rates of 32% with conventional mesh and 63% with suture-only repair, creating a multibillion-dollar clinical cost

- Hernia Prevention: 4–5 million abdominal incisions (laparotomies) performed annually in the U.S., with hernias resulting after approximately 25% of these procedures

Intellectual Property

- Origin: Technology invented by Dr. Howard Levinson at Duke University and licensed to Deep Blue Medical Advances

- Patents: Patent-pending weave technology for T-Line mesh extensions

- AUTM Recognition: Featured in the AUTM Better World Project (2025) for successful academic-to-commercial technology transfer

Company Overview

Corporate Information

Legal Name: Deep Blue Medical Advances, Inc.

Founded: 2015

Headquarters: Durham, North Carolina, USA

Company Type: Privately held corporation

Industry: Medical Devices / General Surgery / Hernia Repair

Website: www.deepbluemedical.com

Leadership Team

Chief Executive Officer & Director: Bill Perry

- 30 years of experience in medical device start-ups; led or contributed to multiple exits, venture financings, an IPO, 21 medical product introductions, 20+ business development deals, and multiple regulatory approvals

Founder, Chief Medical Officer & Director: Dr. Howard Levinson, MD

- Chair of Plastic Surgery Division, Eastern Virginia Medical School / Sentara; Past-President, ASPS Plastic Surgery Foundation; surgeon-inventor of the T-Line technology

Chief Operating Officer: Lou Fuqua (elevated April 2026)

- Over 25 years of experience in medical device start-ups; track record of success with 10+ new product introductions, multiple regulatory clearances, international manufacturing partnerships, and Quality Systems implementations

Director of Research & Development: David Ruppert, Ph.D.

- Over 20 years of product development experience in mechanical and biomedical engineering; translates ideas into finished products through computer simulation, experimental methods, material characterization, and product testing

Vice President, Sales: Dave Murrell

- Several years of hernia sales and clinical support experience; track record of crafting relationships with key accounts

Board of Directors

- Bill Perry: CEO, Director

- Dr. Howard Levinson: Founder, CMO, Director

- Mike Bates: MBA, Angel Investor, Band of Angels, Life Science Angels

- Neil Meyer: MBA, CFA, General Partner, BayMed Venture Partners

- Gary Gershony: MD, Founding General Partner, BayMed Venture Partners (appointed 2022)

Investors & Funding

- Series A1 (2022): Led by BayMed Venture Partners

- Series A (April 2026): $5.6 million; oversubscribed; led by BayMed Venture Partners; existing and new investors including Band of Angels and Life Science Angels

- Key Investors: BayMed Venture Partners, Band of Angels, Life Science Angels

Competitive Landscape

- Johnson & Johnson / Ethicon: Global leader in hernia mesh and surgical products

- Medtronic / Covidien: Comprehensive hernia repair portfolio

- Becton Dickinson (BD): Phasix™ and other hernia mesh products

- B. Braun: Major competitor in surgical mesh

- W.L. Gore & Associates: Gore-Tex and other synthetic mesh products

- Atrium (Getinge): C-QUR hernia mesh

Competitive Advantages

- Surgeon-Invented: Technology developed by a practicing plastic surgeon who identified the clinical need firsthand

- Unique Mechanism: Only hernia mesh with integral suture-like extensions that distribute force and eliminate the mesh-suture-tissue interface failure point

- Superior Fixation: 275% greater anchoring strength and 15x more surface area than traditional sutures

- Proven Clinical Track Record: Over 8,000 implantations across 45+ U.S. sites with no adverse events

- Strong IP Position: Patent-pending weave technology with Duke University licensing foundation

- Platform Expandability: T-Line technology applicable across hernia repair, breast surgery, and general soft tissue closure

2026 Strategic Outlook

- Commercial Expansion: Scale U.S. sales team and expand clinical site adoption of T-Line Hernia Mesh following Series A capital injection

- Product Pipeline: Accelerate development of T-Line TCS, T-Line Scaffold for Breast Surgery, Anchor Clip, biosynthetic mesh, and coated anti-adhesion mesh

- Regulatory Advancement: Pursue additional FDA clearances for minimally invasive (laparoscopic) applications and new product variants

- Clinical Evidence: Continue generating peer-reviewed publications and conference presentations to support surgeon adoption and reimbursement

- Market Penetration: Target the $1.1 billion global hernia device market and the broader soft tissue reinforcement opportunity

Contact Information

Global Headquarters

Address: Durham, North Carolina, USA

Website: www.deepbluemedical.com

Keywords: Deep Blue Medical Advances, T-Line Hernia Mesh, hernia repair, soft tissue surgery, surgical mesh, ventral hernia, incisional hernia, mesh fixation, suture pull-through, cheesewiring, Durham, North Carolina, Bill Perry, Howard Levinson, Lou Fuqua, David Ruppert, Duke University, FDA 510(k), sublay, onlay, anchor strength, BayMed Venture Partners, Angel Capital Association, Luis Villalobos Award, AUTM Better World Project